Navigation Links
Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
Date:5/22/2008

WOODCLIFF LAKE, N.J., May 22 /PRNewswire-FirstCall/ -- In an address to shareholders at the company's annual meeting, Medco Health Solutions, Inc. (NYSE: MHS) Chairman and CEO David B. Snow Jr. today underscored the accelerating momentum of key strategic drivers designed to deliver strong continuing earnings growth through 2008 and beyond -- initiatives ranging from generics, mail-order and specialty pharmacy to retaining and winning customers, and advanced clinical innovation.

"Without question, and by every measure, 2007 represented a breakthrough year for Medco and its shareholders as we surpassed every goal we had established across our business. We achieved a series of records in 2007, including record generic dispensing rate of 59.7 percent, and record mail-order dispensing volume of 94.8 million prescriptions," Snow said. "And we're off to a tremendous start in 2008, setting new sales records since becoming a public company, with $5.1 billion in annualized newnamed sales, $4.6 billion in net-new sales, and a 98 percent client retention rate. On top of all this, we are well underway in transforming the practice of pharmacy," Snow said.

"We are very proud of our 2007 and 2008 results. Our 2009 selling season is already off to a very strong start and we currently expect 2009 to represent another strong year for net-new sales. We look forward to sharing the details of our sales progress during our second quarter earnings call," reported Snow.

Medco Named "Most Admired"

Fortune magazine surveyed 622 companies across 64 industry sectors to compile its list of 'America's Most Admired' Companies, and Medco was named the single-most admired company in the category of Healthcare: Pharmacy and Other Services. In rankings across all industries, Medco was second only to Berkshire-Hathaway in the category of Most Admired -- Long-Term Investment, and third behind Apple and Nike in Most Admired -- Innovation. Medco also ranked as the leader in People Management.

"We're justifiably proud of our achievements," Snow said. "We have created the world's most advanced pharmacy and the first full-service and specialized pharmacy practice to deliver superior clinical solutions for members with chronic and complex conditions. Our focus remains on delivering superior clinical and financial outcomes and our future holds considerable opportunity. Medco remains at the head of our industry and at the heart of health."

Voting Results

During the Annual Meeting of Shareholders, Medco shareholders re-elected John L. Cassis, Michael Goldstein and Blenda J. Wilson to its Board of Directors. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent auditors for fiscal year 2008 and approved and ratified Medco's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 1 billion to 2 billion shares. In addition, shareholders voted to defeat a shareholder proposal regarding executive compensation.

Webcast Information

A replay of the webcast of Medco's Annual Meeting of Shareholders is available through the Investor Relations section on Medco's Web site, http://www.medco.com/investor. Slides associated with the presentations made during the meeting will also be available on the site.

RealPlayer or Windows Media Player is required to listen to the webcast. Free downloads of both players are available at the webcast site. The webcast will be available for replay for one year following the presentation.

About Medco

Medco Health Solutions, Inc., (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering approximately one in five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program and those served by its specialty pharmacy segment, Accredo Health Group. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers(R), including its enhanced diabetes pharmacy care practice through the Liberty acquisition. Medco is the highest-ranked independent pharmacy benefit manager on the 2008 Fortune 100 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference
2. Medco Issues $1.5 Billion of Senior Notes
3. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
4. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
5. Medco to Webcast Annual Analyst Day Conference
6. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
7. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
8. Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
9. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, ... ... assay development and manufacturing company, today announced several positive developments that position the ... As a result of the transaction, Craig F. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across ... South Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations ... are down 21 percent in South Texas in the last four years alone. , There ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):